Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19474049 | 0.89 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1TRPA1LMNAHPGD | |
| SCHEMBL105263 | 0.89 | LMNA (0.52) | ALDH1A1TRPA1LMNAHPGDMAPK1 | |
| Hydrochloric Acid SCHEMBL9074406 | 0.87 | LMNA (0.50) | ALDH1A1TRPA1LMNAHPGDMAPK1 | |
| SCHEMBL13428855 | 0.83 | LMNA (0.47) | TRPA1LMNAHPGDMAPK1 | |
| SCHEMBL13995689 | 0.81 | ALDH1A1 (0.67) | SIGMAR1ALDH1A1TRPA1LMNAHPGD | |
| SCHEMBL13995867 | 0.81 | ALDH1A1 (0.67) | SIGMAR1ALDH1A1TRPA1LMNAHPGD | |
| SCHEMBL4680337 | 0.79 | SIGMAR1 (0.66) | SIGMAR1TRPA1LMNASLC6A4CYP1A2 | |
| SCHEMBL3271284 | 0.78 | SIGMAR1 (0.48) | SIGMAR1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10560323 | 0.78 | SIGMAR1 (0.63) | SIGMAR1TRPA1LMNASLC6A4CYP1A2 | |
| SCHEMBL29432962 | 0.78 | TRPA1 (0.47) | SIGMAR1TRPA1HPGDSLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SIGMAR1 115/4885ALDH1A1 2489/4885TRPA1 863/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | SIGMAR1 115/4885ALDH1A1 2489/4885TRPA1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.